Inspirata

Inspirata, Inc. helps patients fighting cancer—and the clinicians they trust—to make every moment matter. We are an oncology informatics company that offers several innovative software solutions leveraging scalable AI and NLP in the clinical trial and cancer registry spaces. Refined over two decades in collaboration with the National Cancer Institute (NCI) and used by hundreds of healthcare institutions globally, our proprietary AI/NLP engine is at the heart of Trial Navigator, our growing suite of fully automated clinical trial matching solutions, and E-Path Plus, our industry-leading cancer registry reporting and data abstraction solution.

4 past transactions

Caradigm

Acquisition in 2018
Caradigm offers enterprise population health management, visual analytics, care management, cloud-hosted intelligence platform, and other services that help healthcare organizations to improve care, reduce costs, and manage risk.

Omnyx LLC

Acquisition in 2018
Omnyx, LLC is a joint venture of GE Healthcare and UPMC (University of Pittsburgh Medical Center) with locations in Pittsburgh, PA and Piscataway, NJ. The company has developed the OmnyxTM IDP solution allowing pathology departments worldwide to move to an all-digital workflow. Their products include image acquisition devices, workflow software, and transformation consulting. Close collaboration with pathologists at UPMC and other institutions along with their relationship with GE Healthcare allows Omnyx to focus its innovation on the needs of anatomic pathologists worldwide. OmnyxTM products are for in vitro diagnostic use for specific clinical applications, and are intended for research use only on other applications. For more information, go to: omnyx.com.
Artificial Intelligence In Medicine is a software engineering firm focused on using informatics to improve healthcare by designing, developing and deploying information systems for the healthcare industry and cancer control.

Precision Medicine Network

Acquisition in 2016
Precision Medicine Network was co-founded in 2011 by Richard Kellner, CEO, and Dr. Mark Boguski, CMO. PMNI was an outgrowth of the Genomic Medicine Initiative at Harvard Medical School in 2009. The company’s mission is to provide “Fluency in the language of Precision Medicine™” as a basis of connecting providers, patients and payers to overcome barriers and realize the potential of precision healthcare. This is accomplished through “Crosswalk Insight™: Oncology,” a platform designed to accelerate the rational adoption of precision medicine. Current users of the system include medical, surgical and radiation oncologists, pathologists and laboratory medicine professionals, pharmaceutical companies, clinical trial developers, diagnostics companies, life science toolmakers, health system executives, medical students, residents and fellows, and oncology nurses and genetic counselors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.